|
|
Post by sylvaing on Dec 23, 2016 19:59:24 GMT -5
How come Scripts does not increases faster?
Anybody has a good answer?
|
|
|
|
Post by sportsrancho on Dec 23, 2016 20:12:05 GMT -5
How come Scripts does not increases faster? Anybody has a good answer? My questions: How many reps are getting in to see the doctors? Are they just dropping off samples? Are they calling ahead and asking for a hour of the doctors time in order to give a real presentation? Are they just sent to SNY old areas? What is the game plan? If they can't get in to see the doctors what's plan B? And what are they being trained to do exactly? I don't have a answer because I don't really have any info. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 23, 2016 20:42:42 GMT -5
How come Scripts does not increases faster? Anybody has a good answer? My questions: How many reps are getting in to see the doctors? Are they just dropping off samples? Are they calling ahead and asking for a hour of the doctors time in order to give a real presentation? Are they just sent to SNY old areas? What is the game plan? If they can't get in to see the doctors what's plan B? And what are they being trained to do exactly? I don't have a answer because I don't really have any info. did you email Mike those questions? Even if you dont get an answer, its worth sending them. His honeymoon phase is over and there is no SNY $ coming any more. Jun 2017 is the deadline for results. |
|
|
|
Post by sluggobear on Dec 23, 2016 23:18:37 GMT -5
I'm still worried they can sell Afrezza without drastic change in strategy. If it is true that PBMs and insurance companies told sanofi that Afrezza would never be better than tier 3 then pricing change is in order. Obviate the insurance companies.
Undersell all prandials and create a buzz for "the cheapest prandial insulin! And it is easier to use (it's INHALED!). Thus AFREZZA will likely improve patient compliance".
|
|
|
|
Post by sluggobear on Dec 23, 2016 23:20:25 GMT -5
I'm still worried they can sell Afrezza without drastic change in strategy. If it is true that PBMs and insurance companies told sanofi that Afrezza would never be better than tier 3 then pricing change is in order. Obviate the insurance companies. Undersell all prandials and create a buzz for "the cheapest prandial insulin! And it is easier to use (it's INHALED!). Thus AFREZZA will likely improve patient compliance". BTW the statement about insurance companies telling Sanofi they would never get better coverage than tier 3 was in a thread on this board somewhere but I could not find it. |
|
|
|
Post by pguererro on Dec 24, 2016 7:41:39 GMT -5
Access to physicians is about 50-70% in most territories, however many of these accessible docs are seen only during lunches. It sometimes takes 2-3 months to "see" the prescribers. So being out in the field now for 5 mos I have just recently seen some of the endos for the first time. After thoroughly reviewing Afrezza the interest in the product allows better access in the future due to the docs elevated interest. Many docs are still in a wait and see approach. The 6 month marketing blackout did Afrezza no favors. Many of my endos have just written their first new start on Afrezza in the past few weeks.
|
|
|
|
Post by sportsrancho on Dec 24, 2016 8:49:40 GMT -5
Access to physicians is about 50-70% in most territories, however many of these accessible docs are seen only during lunches. It sometimes takes 2-3 months to "see" the prescribers. So being out in the field now for 5 mos I have just recently seen some of the endos for the first time. After thoroughly reviewing Afrezza the interest in the product allows better access in the future due to the docs elevated interest. Many docs are still in a wait and see approach. The 6 month marketing blackout did Afrezza no favors. Many of my endos have just written their first new start on Afrezza in the past few weeks. Thank you for explaining and for all your hard work! Makes sense now:-) |
|
|
|
Post by promann on Dec 24, 2016 9:17:54 GMT -5
Access to physicians is about 50-70% in most territories, however many of these accessible docs are seen only during lunches. It sometimes takes 2-3 months to "see" the prescribers. So being out in the field now for 5 mos I have just recently seen some of the endos for the first time. After thoroughly reviewing Afrezza the interest in the product allows better access in the future due to the docs elevated interest. Many docs are still in a wait and see approach. The 6 month marketing blackout did Afrezza no favors. Many of my endos have just written their first new start on Afrezza in the past few weeks. Thanks for your explanation. It must be hard to read on pro boards share holders frustrations with the script numbers remaining flat. Hopefully there are hundreds of appointments lined up in the coming weeks with endos I'm sure phone calls are being made each and everyday all day long arranging meetings with doctors and if it takes 2-3 months I'm hoping you reps will be very busy. One thing you said that I've heard before which is very concerning is ( Many docs are still in a wait and see approach.) They need to understand that Afrezza is the best treatment for PWD and if all the docs had the wait and see approach that this drug will look like a failure. I hope the reps are showing many examples of people who are having so much success and showing how the wait and see time is done. It works and it's been working very well for a long time now. Thank you for your commitment to helping to sell this drug that will better PWD lives. |
|
|
|
Post by sylvaing on Dec 24, 2016 11:05:46 GMT -5
For Reps activity and results...compare to other insulin launch...this is the Worst....
In addition...renewallss are abissismal
And no proof on the FDA site that a change in the product monograph has been requested...if anybody has a link please provide.
Same for RSL if any links that confirms....please provide...
MNKD Needs RESULTS no Baloonn....!!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 24, 2016 11:17:19 GMT -5
And no proof on the FDA site that a change in the product monograph has been requested...if anybody has a link please provide. you should have known label change applications are not public and care confidential to the label requester and fda. |
|
|
|
Post by nylefty on Dec 24, 2016 11:49:19 GMT -5
And no proof on the FDA site that a change in the product monograph has been requested...if anybody has a link please provide. you should have known label change applications are not public and care confidential to the label requester and fda. But...but...nothing can be true unless there's a link! (sarcasm) |
|
|
|
Post by sayhey24 on Dec 26, 2016 19:53:55 GMT -5
Access to physicians is about 50-70% in most territories, however many of these accessible docs are seen only during lunches. It sometimes takes 2-3 months to "see" the prescribers. So being out in the field now for 5 mos I have just recently seen some of the endos for the first time. After thoroughly reviewing Afrezza the interest in the product allows better access in the future due to the docs elevated interest. Many docs are still in a wait and see approach. The 6 month marketing blackout did Afrezza no favors. Many of my endos have just written their first new start on Afrezza in the past few weeks. Its a shame but not surprising there seems little interest from the doctors in seeing you and now after 5 months you are just now seeing the endos. It seems that you need to quickly raise the interest level of these doctors otherwise there is a pretty good chance after you have your meetings your info may end up in the trash. I bet if you stood in the endos parking lot and handed afrezza info to everyone going in to the office the doc would ask what you are doing and ask you to leave or ask you to come in. Either way they won't forget afrezza and you will get to meet the good doctor a lot sooner. Now most of these endos are managing to 7.0 and they think they are doing a great job at that level. Microvascular damage begins to occur at blood glucose levels of 140 which is 6.5. So,"6.5 is bad and 7.0 is really bad - What's your A1c" is a nice catch phrase for your handout. |
|
|
|
Post by falconquest on Dec 26, 2016 20:20:40 GMT -5
sayhey,
This is why I used to think that Mannkind's strategy of targeting Endo's and educating them first made sense. However, now I am starting to believe that you have to go right to the patient and create a "pull through" demand for Afrezza. Those doctors who jump on the band wagon will be rewarded while those stuck in the old needle paradigm will fall by the wayside.
|
|
|
|
Post by saxcmann on Dec 26, 2016 22:37:55 GMT -5
sayhey, This is why I used to think that Mannkind's strategy of targeting Endo's and educating them first made sense. However, now I am starting to believe that you have to go right to the patient and create a "pull through" demand for Afrezza. Those doctors who jump on the band wagon will be rewarded while those stuck in the old needle paradigm will fall by the wayside. Same Falcon. Endos need push from patients because docs are misinformed and uneducated about afrezza. Endos rely on high level gurus to teach and disseminate new drug information. Afrezza has none or very little. Big pharma spends billions to get this info to providers. Sanofi and Novo say what about afrezza?...Hmmm? Why would a doctor prescribe if they don't understand it or have false information? Docs simply suggest false roadblocks to patient so they don't have to prescribe it! No insurance coverage...pulmonary issues...multiple appts needed for spirometry test...etc. Patient "pull through" is needed so they'll be forced or they'll lose patients to other providers in my opinion. |
|
|
|
Post by pguererro on Dec 27, 2016 10:38:18 GMT -5
Clarification: We are not "just now" seeing endos after 5 mos. Our targets generally consist of around 80% endos and 20% internal med/family practice. Only a small percentage of endos have "just been seen" recently due to access issues. Most endos have been seen regularly since day 1 of relaunch. I don't want to confuse the board. My point was it takes different amounts of time for different prescribers before you see the light bulb go on above their head and I do COMPLETELY understand the time issue with this relaunch. There is momentum building with Afrezza in the field. Trx and refills are extremely frustrating, but with the message of importance of titration I believe this will turn around. Thanks for the passion you all have for the Afrezza. Just by reading your messages I know you all are very well informed about the product. I can assure you the passion is equaled in the field!
|
|
